So-Young International Reports Significant Net Losses, Declining Margins, and Confirms PFIC Status for 2025
Summary
So-Young International reported a substantial net loss of RMB 242.3 million in 2025, following an even larger loss in 2024, alongside a significant drop in gross margin and continued negative operating cash flow, while also confirming its Passive Foreign Investment Company (PFIC) status for U.S. tax purposes.
Key Events
-
Financial Performance Deterioration
Reported a net loss of RMB 242.3 million (US$34.6 million) in 2025, following a RMB 589.5 million loss in 2024, a sharp decline from a net income of RMB 21.3 million in 2023.
-
Gross Margin Decline
Gross margin significantly decreased to 47.8% in 2025 from 61.3% in 2024 and 63.7% in 2023.
-
Negative Operating Cash Flow
Experienced negative cash flow from operating activities for the second consecutive year, reaching RMB 105.4 million (US$15.1 million) in 2025.
-
Goodwill Impairment
Recorded a substantial goodwill impairment of RMB 540.0 million in 2024 related to the Wuhan Miracle acquisition, indicating underperformance of the acquired business.
Analysis
The 20-F filing reveals a company facing significant financial headwinds, marked by consecutive net losses, a sharp decline in gross margins, and persistent negative operating cash flow. The substantial goodwill impairment in 2024 underscores challenges with past acquisitions. While the company is attempting to return capital to shareholders through dividends and share repurchases, these actions occur against a backdrop of deteriorating core profitability. The confirmed PFIC status for U.S. investors adds a material negative tax consideration. Investors should closely monitor the company's ability to reverse its profitability trends and generate positive cash flow from operations, especially given the competitive and evolving nature of the online medical aesthetic service industry in China.
At the time of this filing, SY was trading at $2.78 on NASDAQ in the Technology sector, with a market capitalization of approximately $285.6M. The 52-week trading range was $0.74 to $6.28. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.